AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20804630
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no cranberry treatment)
Trial: 14983613
Drug: Lipid clinic
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid clinic model intervention including diet, medication, and follow-up by nurses and physicians.
Trial: 14983613
Drug: Usual practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual practice control group treatment by general internists.
Trial: 1314147
Drug: Fragmin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin (5000 IU subcutaneously once daily for six days)
Trial: 2982534
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of sodium bicarbonate
Trial: 2982534
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of ammonium chloride
Trial: 30368584
Drug: H3B-6527 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3B-6527 (200 mg dose) after a high-fat meal
Trial: 30368584
Drug: H3B-6527 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3B-6527 (200 mg dose) after fasting
Trial: 29901710
Drug: Mediterranean Pattern
RxNorm normalized name: Thynnus mediterraneus flesh
DrugBank: Northern bluefin tuna (DB14162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean Pattern with 500 g lean, unprocessed red meat (Med-Red)
Trial: 29901710
Drug: Mediterranean Pattern
RxNorm normalized name: Thynnus mediterraneus flesh
DrugBank: Northern bluefin tuna (DB14162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean Pattern with 200 g lean, unprocessed red meat (Med-Control)
Trial: 22179735
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) 3 g daily
Trial: 18807577
Drug: D-003 5
RxNorm normalized name: 5-HYDROXYTRYPTOPHAN, D-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-003 5 mg/d
Trial: 10421537
Drug: Chemoradiation (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation (5000 cGy, Cisplatin 75 mg/m2, Fluorouracil 1000 mg/m2 for 4 days)
Trial: 24108526
Drug: Esmolol (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (continuous infusion titrated to maintain heart rate between 80/min and 94/min)
Trial: 15668416
Drug: Intraduodenal levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal levodopa/carbidopa infusion
Trial: 15668416
Drug: Conventional combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional combination therapies
Trial: 12036647
Drug: Topical ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ropivacaine 1%
Trial: 12036647
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 4%
Trial: 9782681
Drug: CNS prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS prophylactic chemotherapy
Trial: 2905187
Drug: Fraxiparin (7500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fraxiparin (7500 anti-Xa units, once daily)
Trial: 2905187
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (5000 units, three times daily)
Trial: 12528545
Drug: Total flavones
RxNorm normalized name: flavone
DrugBank: Flavone (DB07776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total flavones of Hippophae rhamnoides L. (TFH)
Trial: 12528545
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist nifedipine
Trial: 31680083
Drug: 1% amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% amitriptyline gel
Trial: 31680083
Drug: Standard conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conventional treatment
Trial: 29481765
Drug: ASSIST-linked brief
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASSIST-linked brief intervention (10-step BI) for illicit drug use
Trial: 22763801
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 20 mg for weeks 1-4, 40 mg for weeks 5-8
Trial: 22763801
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium (LOS) 50 mg for weeks 1-4, 100 mg for weeks 5-8
Trial: 11907289
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily for a minimum of 12 weeks
Trial: 11907289
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for 4 weeks followed by 250 mg twice daily for a minimum of 12 weeks
Trial: 11907289
Drug: Bosentan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (both doses)
Trial: 30392864
Drug: Cognitive-behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral and motivational interviewing family-based weight loss treatment
Trial: 28237048
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment PDD (weeks 1‐7)
Trial: 25492848
Drug: Isosorbide-5-mononitrate (5-ISMN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fasting conditions
Trial: 25492848
Drug: Isosorbide-5-mononitrate (5-ISMN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fed conditions
Trial: 19500381
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (500 mg iron polymaltose, single dose)
Trial: 19500381
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (2 ferrous sulphate slow-release tablets daily)
Trial: 6391157
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg daily for three weeks)
Trial: 29409728
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (ERN) treatment
Trial: 21056314
Drug: Microdose GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microdose GnRH agonist flare (MF)
Trial: 21056314
Drug: GnRH antagonist/letrozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH antagonist/letrozole
Trial: 12042457
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of vitamin B-6
Trial: 3142984
Drug: Parenteral lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral lipid infusion (IL) (Vitrum)
Trial: 3142984
Drug: No parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No parenteral lipid infusion (NL)
Trial: 26479162
Drug: Hydrocodone/Acetaminophen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/Acetaminophen (5 mg/325 mg)
Trial: 24521629
Drug: Niacin 750
RxNorm normalized name: niacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 750 mg/day
Trial: 24521629
Drug: Niacin 1500
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 1500 mg/day
Trial: 24521629
Drug: Fenofibrate 320
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 320 mg/day
Trial: 19162468
Drug: Phenylephrine (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (40-120 microg, administered as intermittent i.v. bolus)
Trial: 17204681
Drug: Anticoagulants (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (unfractionated heparin or low‐molecular‐weight heparin or heparinoids)
Trial: 11257244
Drug: Alcohol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.4 g/kg p.o., approximately 2‐3 standard drinks)
Trial: 11257244
Drug: Controlled alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled alcohol intake (0.8 g/kg/day)
Trial: 9444594
Drug: LD-PDGF/IGF-I (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD-PDGF/IGF-I (50 micrograms/ml each of rhPDGF-BB and rhIGF-I in a gel vehicle)
Trial: 9444594
Drug: HD-PDGF/IGF-I (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-PDGF/IGF-I (150 micrograms/ml each of rhPDGF-BB and rhIGF-I plus vehicle)
Trial: 7524312
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid antibody testing for hepatitis C
Trial: 3226754
Drug: High-Dosage Regimen
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dosage Regimen (HDR; n = 51) - NS 550 mg every 8 h for 3 days
Trial: 3226754
Drug: Low-Dosage Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dosage Regimen (LDR; n = 49) - Initial dose of NS 550 mg followed by NS 275 mg every 8 h through day 3
Trial: 4132247
Drug: FSH/LH-RH treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH/LH-RH treatment
Trial: 28103841
Drug: Usual Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual Nicotine Content (11.6 mg)
Trial: 28103841
Drug: Reduced Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Nicotine Content (progressively reduced from 11.6 mg to 0.2 mg)
Trial: 26252522
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg (NMBA group)
Trial: 21237635
Drug: Manual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual and manipulative therapy (MMT)
Trial: 7879405
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment alone (control)
Trial: 31891824
Drug: Any dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any dose as wP
Trial: 23845010
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of universal and selective interventions
Trial: 20482894
Drug: Accelerated hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hand BMD loss (>‐0.003 g/cm2) in the first year of RA
Trial: 20482894
Drug: Anti-citrullinated protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-citrullinated protein antibody positivity
Trial: 16210834
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 2.5 mg (n = 79)
Trial: 16210834
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 5 mg (n = 77)
Trial: 16210834
Drug: Tibolone of
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone of 2.5 mg (n = 76)
Trial: 16210834
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (Ca) of 1,000 mg (n = 54)
Trial: 10323625
Drug: Pseudoephedrine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine (1 mg/kg body weight)
Trial: 1908584
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg PO)
Trial: 29862491
Drug: 0.5% colchicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% colchicine cream
Trial: 21203389
Drug: IST and
RxNorm normalized name: Wrist and Arm Immobilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IST and treatment with SP
Trial: 21203389
Drug: IST and
RxNorm normalized name: Wrist and Arm Immobilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IST and treatment with AQ+AS
Trial: 11948271
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir and Oral valganciclovir
Trial: 10451813
Drug: Oral 17
RxNorm normalized name: polyoxypropylene (17)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17 beta‐estradiol
Trial: 10451813
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐estradiol
Trial: 8519718
Drug: Sitting position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Trial: 8519718
Drug: Supine position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Trial: 2130290
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg phenobarbital
Trial: 2130290
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg phenobarbital
Trial: 28669962
Drug: Dexmedetomidine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.25 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Trial: 28669962
Drug: Dexmedetomidine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.50 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Trial: 28669962
Drug: Dexmedetomidine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.75 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Trial: 17719702
Drug: Plant sterol-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol-enriched products (20 g low-fat margarine and 250 ml low-fat milk delivering 2.3g plant sterols/d)
Trial: 15601557
Drug: Intratumoral H101
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral H101 injection combined with PF regimen (cisplatin + 5-fluorouracil)
Trial: 15601557
Drug: Intratumoral H101
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral H101 injection combined with AF regimen (adriamycin + 5-fluorouracil)
Trial: 9551737
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 microg at 30 L x min[‐1]
Trial: 9551737
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 microg at 90 L x min[‐1]
Trial: 9551737
Drug: Placebo at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at 30 L x min[‐1]
Trial: 9551737
Drug: Placebo at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at 90 L x min[‐1]
Trial: 7020917
Drug: R.T. plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R.T. plus L-PAM
Trial: 28730328
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine patch (5, 10, 15, and 20 μg/h)
Trial: 28730328
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol (150, 200, 250, and 300 mg)
Trial: 19777852
Drug: Dachaihu soup
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dachaihu soup once daily for 7 days
Trial: 18085153
Drug: Acup-moxibustion plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acup-moxibustion plus western medicine
Trial: 9370106
Drug: Exogenous GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous GLP-1 (administered i.v. or s.c.)
Trial: 4011640
Drug: 0.66 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.66 ml/kg of body weight
Trial: 4011640
Drug: 1.2 ml/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 ml/l of total body water
Trial: 31325345
Drug: 17% watery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17% watery solution of glycerol
Trial: 26778329
Drug: Ranibizumab or
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab or Bevacizumab treatment for CME
Trial: 22380577
Drug: Bisphosphonates (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates (weekly alendronate/risedronate)
Trial: 20215101
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of search by story topic and writer profile
Trial: 17921395
Drug: Custards containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custards containing 20 g cooked acetylated high‐amylose maize starch (HAMSA)
Trial: 17921395
Drug: Custards containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custards containing 20 g cooked propionylated high‐amylose maize starch (HAMSP)
Trial: 17921395
Drug: Custards containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custards containing 20 g cooked butyrylated high‐amylose maize starch (HAMSB)
Trial: 16160589
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg doxazosin/d
Trial: 16160589
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg doxazosin/d
Trial: 11865965
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day synthetic conjugated estrogens (n = 35)
Trial: 10075186
Drug: Treatment videotape
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment videotape
Trial: 7728980
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of 300 g of cooked Brussels sprouts per day for 1 week
Trial: 1922194
Drug: Amorolfine 50
RxNorm normalized name: amorolfine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine 50 mg
Trial: 1922194
Drug: Amorolfine 100
RxNorm normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine 100 mg
Trial: 1922194
Drug: Clotrimazole 500
RxNorm normalized name: clotrimazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 500 mg
Trial: 6348177
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg acyclovir intravenously three times daily
Trial: 24861583
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g acetazolamide
Trial: 18204148
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg/day, n=30)
Trial: 16354891
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (triphasic ethinyl estradiol 35 microg + norethindrone 0.5 to 1 mg for 12 cycles of 28 days)
Trial: 8018766
Drug: Interferon-alpha (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (alpha n-1 IFN) treatment at a dosage of 3 MU/day subcutaneously for 5 months
Trial: 31721277
Drug: Otaplimastat 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otaplimastat 80 mg (administered twice daily for 3 days)
Trial: 31721277
Drug: Otaplimastat 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otaplimastat 40 mg
Trial: 31721277
Drug: Otaplimastat 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otaplimastat 80 mg
Trial: 11832440
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and pentagastrin
Trial: 10412851
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg amoxicillin plus 125 mg clavulanic acid (Augmentin), every 8 h for 10 days
Trial: 2321778
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl
Trial: 2321778
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl plus 3.33 micrograms/ml epinephrine
Trial: 2321778
Drug: Lidocaine test
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine test dose
Trial: 2321778
Drug: 2-chloroprocaine test
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-chloroprocaine test dose